Alejandro Abner Garcia Leon
YOU?
Author Swipe
View article: Associations between type III interferons, obesity and clinical severity of COVID-19
Associations between type III interferons, obesity and clinical severity of COVID-19 Open
Introduction Severe COVID-19 is characterized by hyperimmune host responses contributing to airway damage and acute respiratory distress syndrome. Type III interferons (IFN), including IFN lambda 4 (IFNλ4), expressed in individuals harbori…
View article: Associations Between the Gut Microbiome, Inflammation, and Cardiovascular Profiles in People With Human Immunodeficiency Virus
Associations Between the Gut Microbiome, Inflammation, and Cardiovascular Profiles in People With Human Immunodeficiency Virus Open
Background Inflammation and innate immune activation are associated with chronic human immunodeficiency virus (HIV) infection, despite effective treatment. Although gut microbiota alterations are linked to systemic inflammation, their rela…
View article: Immunogenicity, Reactogenicity and Safety to Assess Booster Vaccinations with BNT162b2 or Full-Dose mRNA-1273 in Adults ≥75 Years (EU-COVAT-1-AGED) – Final Report
Immunogenicity, Reactogenicity and Safety to Assess Booster Vaccinations with BNT162b2 or Full-Dose mRNA-1273 in Adults ≥75 Years (EU-COVAT-1-AGED) – Final Report Open
View article: Immunogenicity and Reactogenicity of a First Booster with NT162b2or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1)
Immunogenicity and Reactogenicity of a First Booster with NT162b2or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1) Open
View article: Immunogenicity, Reactogenicity and Safety of a Second Booster with BNT162b2 or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1-AGED Part B)
Immunogenicity, Reactogenicity and Safety of a Second Booster with BNT162b2 or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1-AGED Part B) Open